breast cancer profile

breast cancer profile

(1) A battery of tests performed on a serum sample to screen for breast cancer—e.g., BRCA1, BRCA2, urine CEA, CA 15-3. This particular profile is not widely used to screen for breast cancer as it has a relatively low diagnostic yield.
(2) A proprietary battery (Symphony suite) of assays performed on paraffin-embedded tissue to provide a decision support system for managing breast cancer.

Symphony suite
MammaPrint—Determines risk of recurrence.
BluePrint—Determines molecular subtypes.
TargetPrint—Determines ER, PR and HER2 status.
TheraPrint—Identifies alternative types of therapy for metastatic disease.
Mentioned in ?
References in periodicals archive ?
Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a peer-reviewed publication.
The Insight Dx Breast Cancer Profile helps physicians identify the probability of a patient's cancer recurring and assess the need for chemotherapy.
The Clarient Insight(R) Dx Breast Cancer Profile Assists Physicians In Identifying Recurrence Risk and the Need for Chemotherapy
Unlike other assays used to determine the likelihood of recurrence, the Clarient Insight Dx Breast Cancer Profile uses a combination of pathology risk factors and molecular markers to categorize patients as either high or low risk.
The Clarient Insight Dx Breast Cancer Profile combines three traditional pathology staging risk factors with seven key molecular markers.
Nasdaq:CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, announced today that new data will be presented during the San Antonio Breast Cancer Symposium, validating Clarient's new prognostic breast cancer profile - Clarient Insight(TM) Dx.
We are very excited that these published results validate our Clarient Insight Dx Breast Cancer Profile," said Ron Andrews, Clarient's Chief Executive Officer.
This marker set has now been validated by Clarient in subsequent trials and those data will be published in the coming months as Clarient continues the launch phase of the Clarient Insight Dx Breast Cancer Profile.
Clarient Insight(TM) Dx Breast Cancer Profile Represents First Molecular Test Applicable to All Stages of Operable Breast Cancer
The new offering, called Clarient Insight(TM) Dx Breast Cancer Profile, will be sold by Clarient through an exclusive license agreement with Prediction Sciences, a La Jolla, CA-based company that develops high-value molecular diagnostics for disease detection, prognosis and selection of appropriate therapy.
Clarient's Insight Dx Breast Cancer Profile is a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy.
The important discovery of a predictive breast cancer profile and its validation in an independent study has attracted much attention as it is superior to classical criteria such as the St.

Full browser ?